Analyst consensus rating
ANI Pharmaceuticals Analyst Rating: Buy
ANIP is rated Buy by 8 analysts with a $108.38 target. As of 2026-08-31.
Direct answer
ANI Pharmaceuticals's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $108.38.
Forecast evidence checked August 31, 2026.
Get free ANI Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $73.25
- Average price target
- $108.38
- High price target
- $121.00
- Low price target
- $90.00
- Low target gap
- +22.9%
- Target upside
- +48%
- High target gap
- +65.2%
- Target range width
- 42.3%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ANI Pharmaceuticals?
ANI Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $108.38.
How far are ANI Pharmaceuticals's low and high targets from the recorded price?
The low target implies +22.9%, while the high target implies +65.2%.
How many analysts are included in ANI Pharmaceuticals's consensus?
The verified consensus includes 8 analysts.
How is ANI Pharmaceuticals's target upside or downside calculated?
The average target of $108.38 is divided by the recorded price of $73.25, then one is subtracted to produce +48%. This does not guarantee a future return.
When was ANI Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.